JNJ vs RMD

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

ResMed Inc. (RMD) remains a robust, highly profitable, and well-managed global leader in sleep apnea and respiratory care. Its Q2 fiscal 2026 results showed healthy 11% YoY revenue growth and strong margins, with a very solid balance sheet. However, this analysis specifically targets '10x growth potential within the next 3-5 years.' Given RMD's current large-cap status ($32.64B), achieving a marke...